Biofilm-based Healthcare-associated Infections: Volume II

197 Pages·2015·4.907 MB·English

by  Gianfranco Donelli (eds.)

Advances in Experimental Medicine and Biology 831
Gianfranco Donelli E ditor
Biofi lm-based
Healthcare-
associated
Infections
Volume II
Advances in Experimental Medicine
and Biology
Volume 831
Editorial Board
Irun R. Cohen, The Weizmann Institute of Science, Rehovot, Israel
N. S. Abel Lajtha, Kline Institute for Psychiatric Research, Orangeburg,
NY, USA
John D. Lambris, University of Pennsylvania, Philadelphia, PA, USA
Rodolfo Paoletti, University of Milan, Milan, Italy
For further volumes:
http://www.springer.com/series/5584

Gianfranco Donelli
Editor
Biofi lm-based
Healthcare-associated
Infections
Volume II
Editor
Gianfranco Donelli
Microbial Biofi lm Laboratory
Fondazione Santa Lucia IRCCS
Rome , Italy
ISSN 0065-2598 ISSN 2214-8019 (electronic)
ISBN 978-3-319-09781-7 ISBN 978-3-319-09782-4 (eBook)
DOI 10.1007/978-3-319-09782-4
Springer Cham Heidelberg New York Dordrecht London
Library of Congress Control Number: 2014954798
© Springer International Publishing Switzerland 2015
This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or
part of the material is concerned, specifi cally the rights of translation, reprinting, reuse of
illustrations, recitation, broadcasting, reproduction on microfi lms or in any other physical way,
and transmission or information storage and retrieval, electronic adaptation, computer software,
or by similar or dissimilar methodology now known or hereafter developed. Exempted from this
legal reservation are brief excerpts in connection with reviews or scholarly analysis or material
supplied specifi cally for the purpose of being entered and executed on a computer system, for
exclusive use by the purchaser of the work. Duplication of this publication or parts thereof is
permitted only under the provisions of the Copyright Law of the Publisher’s location, in its
current version, and permission for use must always be obtained from Springer. Permissions for
use may be obtained through RightsLink at the Copyright Clearance Center. Violations are liable
to prosecution under the respective Copyright Law.
The use of general descriptive names, registered names, trademarks, service marks, etc. in this
publication does not imply, even in the absence of a specifi c statement, that such names are
exempt from the relevant protective laws and regulations and therefore free for general use.
While the advice and information in this book are believed to be true and accurate at the date of
publication, neither the authors nor the editors nor the publisher can accept any legal responsibility
for any errors or omissions that may be made. The publisher makes no warranty, express or
implied, with respect to the material contained herein.
Printed on acid-free paper
Springer is part of Springer Science+Business Media (www.springer.com)
Contents
1 Persister Cells in Biofi lm Associated Infections ......................... 1
Brian P. Conlon , Sarah E. Rowe , and Kim Lewis
2 Fungal Biofi lms in Human Disease .............................................. 11
Craig Williams and Gordon Ramage
3 Biofi lm-Infected Pressure Ulcers: Current Knowledge
and Emerging Treatment Strategies ............................................ 29
Louise Suleman and Steven L. Percival
4 Microbial Biofi lms and Adverse Reactions
to Gel Fillers Used in Cosmetic Surgery ..................................... 45
Morten Alhede , Lise H. Christensen ,
and Thomas Bjarnsholt
5 Role of Biofi lms in Breast Implant Associated
Infections and Capsular Contracture ......................................... 53
Jose L. del Pozo and Cristina Auba
6 Innovative Strategies for Combating
Biofi lm-Based Infections ............................................................... 69
Roberta J. Melander and Christian Melander
7 Antimicrobial Polymers for Anti- biofi lm Medical
Devices: State-of- Art and Perspectives ....................................... 93
Iolanda Francolini , Gianfranco Donelli , Fernanda Crisante ,
Vincenzo Taresco , and Antonella Piozzi
8 Antimicrobial Photodynamic Therapy
for Treatment of Biofi lm- Based Infections .................................. 119
Merrill A. Biel
9 Anti-biofi lm Agents in Control of Device-Related
Infections ........................................................................................ 137
Salman Ahmed and Rabih O. Darouiche
v
vi Contents
10 Lipid- and Polymer-Based Drug Delivery Carriers
for Eradicating Microbial Biofi lms Causing
Medical Device-Related Infections .............................................. 147
Tamilvanan Shunmugaperumal , Varinder Kaur ,
and Raja Sekharan Thenrajan
Index ....................................................................................................... 191
Contributors
Salman Ahmed Department of Medicine , Baylor College of Medicine and
Michael E. DeBakey Veterans Affairs Medical Center , Houston , TX , USA
Morten Alhede Department of International Health, Immunology, and
Microbiology, Faculty of Health Sciences, U niversity of Copenhagen,
Copenhagen , Denmark
Department of Clinical Microbiology , Hospital of Copenhagen , Copenhagen ,
Denmark
Cristina Auba Department of Plastic Surgery , Clinica Universidad de
Navarra , Pamplona , Spain
Merrill A. Biel E ar, Nose and Throat Specialty Care of MN, Department of
Otolaryngology-Head and Neck Surgery, U niversity of Minnesota,
Minneapolis , MN , USA
Thomas Bjarnsholt Department of International Health, Immunology, and
Microbiology, Faculty of Health Sciences, U niversity of Copenhagen,
Copenhagen , Denmark
Department of Clinical Microbiology , Hospital of Copenhagen , Copenhagen ,
Denmark
Lise H. Christensen Department of Pathology, Herlev Hospital , University
of Copenhagen , Copenhagen , Denmark
Brian P. Conlon Antimicrobial Discovery Center, Department of Biology ,
Northeastern University , Boston , MA , USA
Fernanda Crisante Department of Chemistry , Sapienza University of
Rome , Rome , Italy
Rabih O. Darouiche Department of Medicine , Baylor College of Medicine
and Michael E. DeBakey Veterans Affairs Medical Center, H ouston, T X,
USA
Gianfranco Donelli Microbial Biofi lm Laboratory , Fondazione Santa Lucia
IRCCS , Rome , Italy
Iolanda Francolini Department of Chemistry , Sapienza University of
Rome , Rome , Italy
vii
viii Contributors
Varinder Kaur Department of Pharmaceutical Sciences , Lovely Professional
University , Phagwara , Punjab , India
Kim Lewis Antimicrobial Discovery Center, Department of Biology ,
Northeastern University , Boston , MA , USA
Christian Melander Department of Chemistry , North Carolina State
University , Raleigh , NC , USA
Roberta J. Melander Department of Chemistry , North Carolina State
University , Raleigh , NC , USA
Steven L. Percival Institute of Ageing and Chronic Disease , University of
Liverpool , Liverpool , UK
Surface Science Research Centre , University of Liverpool , Liverpool , UK
Antonella Piozzi Department of Chemistry , Sapienza University of
Rome , Rome , Italy
Jose L. del Pozo Infectious Diseases Division , Clinica Universidad de
Navarra , Pamplona , Spain
Department of Clinical Microbiology , Clinica Universidad de Navarra ,
Pamplona , Spain
Gordon Ramage Infection and Immunity Research Group, Glasgow Dental
School and Hospital, School of Medicine, College of Medical, Veterinary and
Life Sciences , University of Glasgow , Glasgow , UK
Sarah E. Rowe Antimicrobial Discovery Center, Department of Biology ,
Northeastern University , Boston , MA , USA
Tamilvanan Shunmugaperumal Department of Pharmaceutical Sciences ,
Lovely Professional University , Phagwara , Punjab , India
Louise Suleman Institute of Ageing and Chronic Disease , University of
Liverpool , Liverpool , UK
V incenzo T aresco D epartment of Chemistry, S apienza University of
Rome, R ome, I taly
Raja Sekharan Thenrajan Sankaralingam Bhuvaneswari College of
Pharmacy , Sivakasi , TN , India
Craig Williams Institute of Healthcare Associated Infection , University of
the West of Scotland , Paisley , UK
1
Persister Cells in Biofilm
Associated Infections
Brian P. Conlon, Sarah E. Rowe, and Kim Lewis
Persister formation can actually be induced by
1 Introduction exposure to antibiotics of various classes (Dorr
et al. 2010; Johnson and Levin 2013).
Persisters were first identified by Joseph Bigger Persister cells have been identified in vivo and
in 1944 (Bigger 1944). Bigger was the first to have been directly implicated in disease (Conlon
show that penicillin is a bactericidal antibiotic. et al. 2013; Helaine et al. 2014; Mulcahy et al.
He also found that addition of a lethal dose of 2010). They are proposed to be the underlying
penicillin to a population of Staphylococcus reason for the tolerance demonstrated by bacterial
aureus, always resulted in a subpopulation of biofilms. Targeting these dormant persister cells
survivors. These surviving colonies could be with novel antibiotics will allow us to efficiently
regrown and the resulting population could also treat chronic biofilm infections and eradicate
be lysed efficiently with penicillin to yield a bacterial populations (Conlon et al. 2013).
subpopulation of survivors, or persister cells
(Bigger 1944).
Persisters are dormant, phenotypic variants of 2 Mechanisms of Persister
regular cells, capable of surviving in the presence Formation
of high levels of bactericidal antibiotics. They
can be pre-existing in a population, or their The hipA gene was the first gene demonstrated to
formation can be induced by environmental have an impact on persister formation. Moyed
conditions (Balaban et al. 2004; Dorr et al. 2010). and co-authors found that a particular allele of
The relative abundance of persister cells in a pop- this gene, termed hipA7, led to at least a 100-fold
ulation is dependent on the growth phase, with a increase in persister cells formation. In other
particularly high number being observed in the words, antibiotic treatment of a population of
stationary phase (Keren et al. 2004; Conlon et al. E. coli harboring the hipA7 gene, resulted in
2013). Persister cells often display multi-drug 100–1,000 times more survivors than an identical
tolerance, meaning that an individual persister treatment of a wild-type population with a different
can survive for prolonged periods in the presence hipA allele (Falla and Chopra 1998). Importantly,
of a variety of antibiotics (Conlon et al. 2013). the minimal inhibitory concentration (MIC)
of the antibiotics examined in this study, were
identical for the wild-type and hipA7 strains.
B.P.Conlon•S.E.Rowe•K.Lewis(*) A change in MIC suggests the development of
Antimicrobial Discovery Center, Department of
resistance to an antibiotic, not apparent in a high
Biology,NortheasternUniversity,Boston,MA,USA
e-mail: [email protected] persister (hip) phenotype.
G. Donelli (ed.), Biofilm-based Healthcare-associated Infections: Volume II, 1
Advances in Experimental Medicine and Biology 831, DOI 10.1007/978-3-319-09782-4_1,
© Springer International Publishing Switzerland 2015